Posts

Alkermes Advances Alixorexton to Phase 3 for Narcolepsy with Strong Mid-Stage Data

on

Alkermes Ups Bid for Avadel Amid Lundbeck’s Competing Offer in Narcolepsy Drug Takeover Battle

on

Lundbeck Fires First Shot in Bidding War With Alkermes Over Sleep Biotech Avadel

on

Alkermes Pushes Narcolepsy Program to Phase III With Highly Competitive Mid-Stage Data

on

Alkermes Acquires Avadel Pharmaceuticals for $2.1B, Gaining Sleep Drug LUMRYZ and Setting Strategic Evolution

on

Takeda and Alkermes Detail Strong Clinical Results for Orexin Drugs in Narcolepsy – Head-to-Head Race Accelerates

on

Alkermes Advances Narcolepsy Therapy with Promising Phase 2 Trial Results for Alixorexton

on